Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Overexpression of the p53 gene product in canine mammary tumors
Autore:
Haga, S; Nakayama, M; Tatsumi, K; Maeda, M; Imai, S; Umesako, S; Yamamoto, H; Hilgers, J; Sarkar, NH;
Indirizzi:
Nara Med Univ, Dept Anat 2, Kashihara, Nara 6348521, Japan Nara Med Univ Kashihara Nara Japan 6348521 Kashihara, Nara 6348521, Japan Nakayama Vet Hosp, Nara 6308342, Japan Nakayama Vet Hosp Nara Japan 6308342 ayama Vet Hosp, Nara 6308342, Japan Nara Prefectural Inst Publ Hlth, Nara 6308131, Japan Nara Prefectural InstPubl Hlth Nara Japan 6308131 , Nara 6308131, Japan Nara Hlth Ctr, Nara 6308325, Japan Nara Hlth Ctr Nara Japan 6308325Nara Hlth Ctr, Nara 6308325, Japan Sanbe Farma, Div Biotech & Res, Bandung, Indonesia Sanbe Farma Bandung Indonesia ma, Div Biotech & Res, Bandung, Indonesia Med Coll Georgia, Sch Med, Program Cell Signaling, Inst Mol Med & Genet, Augusta, GA 30912 USA Med Coll Georgia Augusta GA USA 30912 Med & Genet, Augusta, GA 30912 USA
Titolo Testata:
ONCOLOGY REPORTS
fascicolo: 6, volume: 8, anno: 2001,
pagine: 1215 - 1219
SICI:
1021-335X(200111/12)8:6<1215:OOTPGP>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
WILD-TYPE P53; BREAST CARCINOMAS; CELL-LINES; PROGNOSTIC-SIGNIFICANCE; PROTEIN; EXPRESSION; SUPPRESSOR; CANCER; MUTATIONS; TISSUES;
Keywords:
canine mammary tumor; immunoelectron microscopy; monoclonal antibody; tumor suppressor gene product;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Haga, S Nara Med Univ, Dept Anat 2, 840 Shijo Cho, Kashihara, Nara 6348521, Japan Nara Med Univ 840 Shijo Cho Kashihara Nara Japan 6348521 21, Japan
Citazione:
S. Haga et al., "Overexpression of the p53 gene product in canine mammary tumors", ONCOL REP, 8(6), 2001, pp. 1215-1219

Abstract

p53, a tumor suppressor gene, is a target of genetic alternations in many human and animal cancers. Compared to normal tissues, cancer tissues overexpress mutant p53 protein thus allowing their detection by a number of immunochemical procedures. To what extent the expression of mutant p53 correlates with dog mammary tumorigenesis has not been fully studied. In the presentstudy, 20 spontaneously arising canine mammary tumors were examined for overexpression of mutant p53. Two different monoclonal antibodies, BP53-12 and PAb122, which recognize different epitopes of the p53 product, were used. The canine tumors in the present study exhibited five different histological types: i) osteosarcoma (n=7); ii) carcinosarcoma (n=4); iii) solid carcinoma (n=5); iv) complex carcinoma (n=3); and v) tubulopapillar carcinoma (n=1). The positive ratios against BP53-12 and PAb122 antibodies were 50% (10/20) and 60% (12/20) respectively. Among these positive samples, 35% (7/20)reacted to both antibodies. Finally, 15 out of 20 tumors showed positivityagainst one of the monoclonal antibodies. Mostly, as in human mammary tumor cells, BP53-12 staining was observed in the nuclei of tumor cells. PAb122staining, however, was confined to cytoplasm of osteosarcoma or carcinosarcoma cells. To confirm the location of the staining, immunoelectron microscopy was done. The results showed that the cytoplasm of cartilage cells in the sarcomas had positive staining. These results indicate that anti-p53 antibodies BP53-12 and PAb122, generated against human p53 are cross reacting with the same molecule in canine cells and that the role of p53 in tumorigenesis is not only confined to tumors in human. Our finding suggests that a combination of p53 monoclonal antibodies should be used to screen, not onlycanine mammary tumors but also human mammary tumors, to obtain a better tumor prognosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 08:01:09